Anti-Human C3/C3b/iC3b/C3dg, Biotin, (clone: 1H8) (Mouse IgG2a)
|
Product Code:
|
CL7637B |
|
Supplier Name:
|
Cedarlane |
|
Size:
|
100ug |
|
Data Sheet:
|
View Data Sheet |
|
Categories:
|
1H8 |
Additional Product Details
|
Applications:
|
WB, F, E |
|
Clone:
|
1H8 |
|
Format:
|
Biotin |
|
Isotype:
|
Mouse IgG2a |
|
Specificity:
|
C3/C3b/iC3b/C3dg |
|
Host:
|
Mouse |
|
Conjugate:
|
Biotin |
|
Species Reactivity:
|
Human |
-
DescriptionCedarlane’s anti-Human C3/C3b/iC3b/C3dg monoclonal antibody specifically binds human C3 as well as the breakdown products C3b, iC3b and C3dg. C3 is the most abundant complement protein in serum. C3 and its cleavage products, C3a and C3b, play a central role in the complement activation cascade. C3b forms an integral part of the C3 and C5 convertases as it promotes complement activation and the subsequent formation of the membrane attack complex. C3a possesses anaphylatoxic as well as various immunoregulatory properties.Also, C3 has been implicated in developmental and non-imflammatory process such as hematopoiesis, skeletal and vascular development and reproduction.Cedarlane’s CL7637 (clone: 1H8) and CL7636 (clone: 7C12) recognize separate, non-overlapping epitopes on C3 fragments. Clone 1H8 is suitable for use in Flow Cytometry, ELISA and Immunofluorescence.______________________________________________________________________________________________________Flow Cytometry Analysis
Balb/c mouse thymocytes incubated with rabbit anti-mouse T cells and then incubated with fresh human serum were stained with anti-C3/C3b/iC3b/C3dg (clone: 1H8) (filled histogram) or mouse IgG2a isotype control (open histogram).
-
References
1) Williams ME, Densmore JJ, Pawluczkowycz AW et al. (2006) Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia. J Immunol. 177(10):7435-43.
2) Beurskens FJ, Lindorfer MA, Farooqui M et al. (2012) Exhaustion of Cytotoxic Effector Systems May Limit MonoclonalAntibody-Based Immunotherapy in Cancer Patients. J Immunol. 188(7):3532-41.
3) Kennedy AD, Beum PV, Solga MD et al. (2004) Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 172(5):3280-8.
4) Lindorfer MA, Pawluczkowycz AW, Peek EM et al. (2010) A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood. 115(11):2283-91.

